Kardigan, Inc. (KARD) Stock Price & How to Invest

Last updated November 2026

Short answer

KARD is Kardigan, a clinical-stage precision cardiovascular biotech that went public on Nasdaq in June 2026, so investing in it is a bet on unproven heart-disease drug candidates rather than current profits or revenue. It suits only investors comfortable with binary, pre-commercial biotech risk. As of November 20, 2026 the shares closed near $12.04, about 25% below the $16.00 IPO price and down about 42% over three months, for a market value near $1.13 billion.

KARD stock price

As of 2026-11-20, Kardigan, Inc. (KARD) last closed at $11.54, down 10.2% over the past month. Over its trading history so far it has traded between $11.54 and $25.90.

KARD last close
$11.54
1 day
-7.83%
1 month
-10.19%
1 year
n/a
Range since listing
$11.54 to $25.90
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Kardigan, Inc.'s investor relations page. Walnut is informational, not investment advice.

KARD key stats

At $11.54 on November 20, 2026, Kardigan, Inc. (KARD) has a market cap of $1.1B.

Market cap
$1.1B
Price to book
1.9

Market cap, P/E and yield are measured at the $11.54 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Kardigan, Inc. (KARD)?

The last two weeks for Kardigan, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • KARD closed at $11.54 on November 20, 2026, down 16.5% over the past five trading days (from $13.82).
  • On November 12, 2026, Kardigan, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 12, 2026, Kardigan, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 13, 2026, Leerink Partners lowered its target to $36.00 from $37.00 (Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Kardigan, Inc. (KARD) do?

Kardigan, Inc. (Nasdaq: KARD) is a clinical-stage precision cardiovascular therapeutics company based in Princeton, New Jersey, founded in 2023 and formerly known as EnCarda. It was created by former executives of MyoKardia, the team behind mavacamten (Camzyos), the hypertrophic cardiomyopathy drug that led to Bristol Myers Squibb's roughly $13 billion acquisition of MyoKardia. Kardigan is developing three late-stage candidates that target the underlying biology of specific heart conditions where treatments are limited: danicamtiv (a cardiac myosin activator in-licensed from BMS) for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. It pairs these programs with the Prolaio AI and real-world-data platform, branded as Cardiac Intelligence, to sharpen trial design.

The investment picture is a classic pre-commercial biotech profile. Kardigan has no product revenue and reported a net loss of roughly $192 million for 2025 and about $56 million for the first quarter of 2026, with an accumulated deficit near $337 million at that point. The second quarter of 2026 added a net loss of about $116.2 million, including research spending of about $56.4 million and a $43.5 million charge from a change in the fair value of contingent milestone liabilities; the loss of $2.89 per share was far wider than the roughly $0.64 analysts expected. Its June 2026 IPO priced 25 million shares at $16.00 and raised over $400 million in gross proceeds (about $460 million with the full overallotment), initially giving a market capitalization of roughly $2 billion. Cash, cash equivalents and investments stood at about $660.7 million on June 30, 2026, which the company says funds multiple clinical readouts and the start of Phase 3 trials for all three programs. The third quarter, reported November 12, brought a net loss of about $58.6 million, or $0.64 per share, narrower than the roughly $1.04 analysts expected, because a $21.8 million benefit from the change in fair value of milestone liabilities offset R&D of about $64.4 million and G&A of about $22.2 million. Cash, cash equivalents and investments fell to about $591.4 million at September 30, 2026. Value here is driven almost entirely by clinical data, not financial results.

The stock has not held its IPO price. It closed near $12.04 on November 20, 2026, down about 42% over three months and about 6% over the past month, near its post-IPO low of about $11.69, which leaves a market value of about $1.13 billion, roughly 1.9 times its cash. The timeline also shifted. On November 6 Kardigan completed enrollment of 156 patients in the Phase 2b KATALYST-AV trial of ataciguat and said the primary endpoint, aortic valve calcium, will be assessed at week 48, which pushes topline data to the second half of 2027 (a Phase 3 update is expected in the first half). Danicamtiv's Phase 2b KINSHIP-DCM data are now guided for the second quarter of 2027 after Cohort 2 enrollment finished, and tonlamarsen's KARDINAL-ASH data moved to the second half of 2027. The eight analysts covering it had an average target of about $41 and a consensus rating of strong buy.

What's driving Kardigan, Inc. (KARD)?

1. Late-stage cardiovascular pipeline

Kardigan carries three programs already in Phase 2b or Phase 2b/3, which is unusually advanced for a company this young. Danicamtiv, ataciguat, and tonlamarsen each target a heart condition with limited or no approved disease-modifying therapy, so positive data could address large unmet needs. The trade-off is that all three still face the standard risk that mid- or late-stage trials miss their endpoints. As of November 2026, danicamtiv's Phase 2b/3 KINSHIP-DCM trial has completed enrollment in Cohort 2 of the Phase 2b portion, with Phase 3 enrolling in both cohorts and Phase 2b topline data expected in the second quarter of 2027. Ataciguat's Phase 2b KATALYST-AV trial completed enrollment of 156 patients and will read out week 48 data in the second half of 2027, replacing the earlier plan for a 24-week interim look, and tonlamarsen's KARDINAL-ASH trial is still enrolling, with topline data now expected in the second half of 2027.

2. MyoKardia pedigree and BMS-sourced asset

The founding team previously developed and won approval for mavacamten at MyoKardia, giving Kardigan credibility in cardiac drug development. Danicamtiv was originally discovered at MyoKardia and advanced by Bristol Myers Squibb before Kardigan in-licensed worldwide rights. That track record helped attract a large IPO, though past success does not guarantee that these specific molecules will succeed.

3. Well-funded runway

Kardigan held about $591.4 million of cash, cash equivalents and investments at September 30, 2026, down from about $660.7 million in June but up from about $335.5 million at the end of 2025 thanks to the June IPO, and says that supports all three programs through data readouts and the start of Phase 3 trials. A funded runway reduces near-term financing pressure, but quarterly spending is rising (R&D was about $64.4 million in the third quarter, up from $49.1 million a year earlier, and G&A more than doubled to about $22.2 million), and future Phase 3 trials mean additional capital raises (and potential dilution) are likely before any product reaches market.

4. AI and real-world-data platform

The Prolaio-based Cardiac Intelligence platform is positioned to use real-world patient data and analytics to inform trial design and patient selection. If it shortens or de-risks development, it could be a differentiator against traditional cardiovascular developers. For now it is a supporting tool, and its impact on actual approval odds is unproven.

What are the risks to Kardigan, Inc. (KARD)?

Kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail. Its S-1 disclosures included going-concern language tied to pre-IPO cash, and while the IPO extended the runway into 2028, the company will likely need to raise more capital and could dilute shareholders. Any negative or delayed data from danicamtiv, ataciguat, or tonlamarsen could sharply reduce the stock, and a post-IPO lock-up expiration may add selling pressure. The shares have already shown that volatility: they fell below the $16.00 IPO price and closed near $12.04 on November 20, 2026, about 42% lower over three months. The November 2026 decision to read ataciguat at week 48 and the slower tonlamarsen enrollment push two of three readouts into the second half of 2027, extending the wait and the cash burn before the main catalysts. Contingent milestone liabilities tied to in-licensed assets can also swing reported losses in both directions, as a $43.5 million fair-value charge in the second quarter of 2026 and a $21.8 million benefit in the third showed. It also competes with larger, better-capitalized cardiovascular players.

What is the Kardigan, Inc. (KARD) forecast?

8 analysts publish price targets on KARD, averaging $41.00 as of November 2026, or +255.3% against the $11.54 share price on November 20, 2026. The published targets run from $25.00 to $50.00, a moderate spread, and the ratings split 9 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full KARD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is KARD a buy or a sell?

We give no verdict on Kardigan, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Late-stage cardiovascular pipeline. Kardigan carries three programs already in Phase 2b or Phase 2b/3, which is unusually advanced for a company this young. The most optimistic published target, $50.00, assumes this works close to its best case.

The case against. Kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail. The most pessimistic target, $25.00, is roughly what KARD is worth if this bites instead.

Read the full bull and bear case on KARD, including what would have to change to break either one. Walnut is not an investment adviser.

Has Kardigan, Inc. (KARD) split its stock?

No. Kardigan, Inc. (KARD) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Kardigan, Inc. (KARD) valued?

Market cap, P/E and dividend yield at today's price are in the KARD key stats above. The business figures below come from Kardigan, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$0 (pre-commercial)
  • Net loss (TTM): ~-$287M
  • Net loss (Q3 2026): ~-$58.6M (incl. ~$21.8M milestone fair-value benefit)
  • Cash & investments (Sept 30, 2026): ~$591M
  • IPO gross proceeds (Jun 2026): ~$400M+ at $16.00 per share

As of November 2026: Kardigan generates no product revenue and funds a growing research budget, producing a net loss of about $58.6 million in Q3 2026 (reduced by a $21.8 million milestone fair-value benefit) and roughly $287 million over the trailing twelve months. Its valuation reflects pipeline potential, not current financials: at about $1.13 billion, the market cap is roughly 1.9 times the ~$591 million of cash, so investors are assigning around $540 million to three mid- and late-stage programs whose main readouts now fall between the second quarter and the second half of 2027. Analysts expect a loss of about $4.53 per share for 2026 and $4.17 for 2027.

Who competes with Kardigan, Inc. (KARD)?

Precision cardiovascular biotechs

Companies such as Cytokinetics, BridgeBio, and Tenaya Therapeutics also target genetic and structural heart diseases with novel mechanisms. They compete with Kardigan for trial patients, talent, and investor capital, and some have programs aimed at overlapping indications like cardiomyopathy.

Large-cap pharma in cardiology

Bristol Myers Squibb (which markets Camzyos and out-licensed danicamtiv), Novartis, and AstraZeneca have deep cardiovascular franchises and resources. Their approved or late-stage therapies set the bar Kardigan's candidates must clear and could reach adjacent patient populations first.

Device and procedural alternatives

For calcific aortic valve stenosis, procedural options such as transcatheter aortic valve replacement from Edwards Lifesciences and Medtronic already exist. A drug like ataciguat must show it can meaningfully slow disease in patients who might otherwise be managed with monitoring or eventual valve replacement.

What stocks are similar to Kardigan, Inc. (KARD)?

Other names that sit close to KARD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Kardigan, Inc. (KARD)

There are three common ways to get KARD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so KARD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where KARD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Kardigan, Inc. (KARD)

Kardigan is a well-funded, pedigreed clinical-stage cardiovascular biotech whose value hinges entirely on trial readouts, which in November 2026 moved later: danicamtiv data are now guided for the second quarter of 2027 and ataciguat and tonlamarsen for the second half. The market has marked the shares down about 25% below the IPO price while it waits.

More on Kardigan, Inc. (KARD)

Whether KARD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KARD a buy or a sell?, and where the stock could go from here in the KARD stock forecast.

For income investors, whether KARD pays a dividend and how the payout looks is covered in does KARD pay a dividend? And to weigh KARD against a peer, read the full side-by-side comparisons: KARD vs BBIO and KARD vs BMY.

Wondering how KARD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Kardigan, Inc.

Ask Walnut's AI anything about KARD and see how it fits what you own.

FAQ

What company is stock ticker KARD?

+

KARD is Kardigan, Inc., a clinical-stage precision cardiovascular therapeutics company that trades on the Nasdaq Global Market. It develops medicines aimed at the underlying biology of specific heart diseases and is based in Princeton, New Jersey.

When did Kardigan go public?

+

Kardigan began trading on Nasdaq on June 18, 2026. It priced its upsized IPO at $16.00 per share for 25 million shares, raising over $400 million in gross proceeds (about $460 million with the full overallotment exercised). As of November 20, 2026 the stock traded near $12.04, about 25% below that IPO price.

Does Kardigan have any revenue or approved products?

+

No. Kardigan is pre-commercial with no product revenue and no approved drugs. Its three candidates are still in clinical trials, so the company reports net losses and depends on outside capital rather than sales.

What drugs is Kardigan developing?

+

Its three late-stage candidates are danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. Danicamtiv was originally discovered at MyoKardia and later advanced by Bristol Myers Squibb before Kardigan licensed it.

Who founded Kardigan?

+

Kardigan was founded in 2023 (originally as EnCarda) by former executives of MyoKardia, the team that developed mavacamten (Camzyos). MyoKardia was acquired by Bristol Myers Squibb for roughly $13 billion, giving the founders a notable cardiovascular track record.

How much cash does Kardigan have?

+

Kardigan reported about $591.4 million of cash, cash equivalents and investments as of September 30, 2026, down from about $660.7 million at June 30 and up from about $335.5 million at December 31, 2025, mainly because of the June IPO. The company says that funds all three programs through data readouts and the start of Phase 3 trials, though further raises are likely before any product could launch.

Why is Kardigan considered high risk?

+

It is a pre-revenue biotech whose value rests on trial outcomes that could fail, with key readouts now spread from the second quarter to the second half of 2027. Its S-1 carried going-concern language tied to pre-IPO cash, it may need more capital, and with no earnings the shares are volatile: they fell from a $16.00 IPO price to about $12.04 by November 20, 2026.

When are Kardigan's key trial results expected?

+

As of November 2026 Kardigan guides to Phase 2b topline data for danicamtiv's KINSHIP-DCM trial in the second quarter of 2027, week 48 topline data from ataciguat's KATALYST-AV trial in the second half of 2027 (with a Phase 3 update in the first half), and tonlamarsen's KARDINAL-ASH data in the second half of 2027. Earlier guidance had all three in the first half of 2027. Those results would be the main catalysts that determine whether the candidates advance toward potential approval, and they carry meaningful binary risk.

How did Kardigan do in its latest quarter?

+

In the third quarter of 2026, reported November 12, Kardigan posted a net loss of about $58.6 million, or $0.64 per share, against roughly $1.04 expected and $60.2 million a year earlier. R&D rose to about $64.4 million and G&A to about $22.2 million, offset by a $21.8 million benefit from the change in fair value of contingent milestone liabilities. Cash and investments were about $591.4 million, and the company updated its readout timelines into 2027. In the second quarter, its first public report, it had lost about $116.2 million, or $2.89 per share.

How has KARD stock performed since its IPO?

+

KARD priced at $16.00 in June 2026 and reached as high as $27.00, but closed near $12.04 on November 20, 2026, down about 42% over three months and about 6% over one month, close to its low of about $11.69. Its market value was about $1.13 billion. Analysts' average target among eight analysts was about $41, with a consensus rating of strong buy.

Why did Kardigan push back its ataciguat results?

+

When it completed enrollment of 156 patients in the Phase 2b KATALYST-AV trial on November 6, 2026, Kardigan said it would assess the primary endpoint, aortic valve calcium, at week 48 along with measures such as aortic valve area and left ventricular mass index, citing new evidence on patient selection and endpoints. That replaces the earlier 24-week interim readout and moves topline data to the second half of 2027, with a Phase 3 update expected in the first half.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Kardigan, Inc.'s investor relations page or your broker before making investment decisions.